Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4)–Deficient Pancreatic Cancer Cells

1 Oct 2006

Abstract excerpt

One of the most common types of genetic alterations in cancer is the loss-of-function mutations in tumor-suppressor genes. Such mutations are usually very specific to cancer cells and present attractive and unique opportunities for therapeutic interventions. However, for various reasons, antitumor agents that target loss-of-function mutations have not been readily identified. In this report, using the deleted in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17018631
DOI: 10.1158/0008-5472.can-05-4602

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4)–Deficient Pancreatic Cancer CellsPMID 17018631Read ↗

Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells.Semantic proximity Read ↗

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with OlaparibSemantic proximity Read ↗

Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair DeficienciesSemantic proximity Read ↗

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approachesSemantic proximity Read ↗

Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21Semantic proximity Read ↗

Targeting tumor suppressor genes for cancer therapy.Semantic proximity Read ↗

Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancerSemantic proximity Read ↗

Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.Semantic proximity Read ↗

Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic CancerSemantic proximity Read ↗

A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancerSemantic proximity Read ↗

Therapeutic relevance of the protein phosphatase 2A in cancer.Semantic proximity Read ↗

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.